Second-line therapy with nivolumab plus ipilimumab for older patients with oesophageal squamous cell cancer (RAMONA): a multicentre, open-label phase 2 trial.

BACKGROUND

The overall survival of patients with advanced and refractory oesophageal squamous cell carcinoma, mostly aged 65 years and older, is poor. Treatment with PD-1 antibodies showed improved progression-free survival and overall survival. We assessed the safety and efficacy of combined nivolumab and ipilimumab therapy in this population.

METHODS

This multicentre, open-label, phase 2 trial done in 32 sites in Germany included patients aged 65 years and older with oesophageal squamous cell carcinoma and disease progression or recurrence following first-line therapy. Patients were treated with nivolumab (240 mg fixed dose once every 2 weeks, intravenously) in the safety run-in phase and continued with nivolumab and ipilimumab (nivolumab 240 mg fixed dose once every 2 weeks and ipilimumab 1 mg/kg once every 6 weeks, intravenously). The primary endpoint was overall survival, which was compared with a historical cohort receiving standard chemotherapy in the intention-to-treat population. This study is registered with ClinicalTrials.gov, NCT03416244.

FINDINGS

Between March 2, 2018, and Aug 20, 2020, we screened 75 patients with advanced oesophageal squamous cell carcinoma. We enrolled 66 patients (50 [76%] men and 16 [24%] women; median age 70·5 years [IQR 67·0-76·0]), 44 (67%) of whom received combined nivolumab and ipilimumab therapy and 22 (33%) received nivolumab alone. Median overall survival time at the prespecified data cutoff was 7·2 months (95% CI 5·7-12·4) and significantly higher than in a historical cohort receiving standard chemotherapy (p=0·0063). The most common treatment-related adverse events were fatigue (12 [29%] of 42), nausea (11 [26%]), and diarrhoea (ten [24%]). Grade 3-5 treatment-related adverse events occurred in 13 (20%) of 66 patients. Treatment-related death occurred in one patient with bronchiolitis obliterans while on nivolumab and ipilimumab treatment.

INTERPRETATION

Patients aged at least 65 years, with advanced oesophageal squamous cell carcinoma might benefit from combined nivolumab and ipilimumab therapy in second-line treatment.

FUNDING

Bristol Myers Squibb.

Informations de copyright

Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests MPE reports receiving funding to conduct the trial from AIO Studien, the regulatory sponsor of the trial, and serving as an advisor with Bristol Myers Squibb. NMB reports receiving research funding and receipt of equipment from Deutsche Forschungsgemeinschaft. RH reports serving as an advisor with Amgen, Astra Zeneca, Bristol Myers Squibb, Boehringer, Daichi, Lilly, Merck, MSD, Pierre Fabre, Roche, and Servier; honoraria for lectures and presentations from Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Boehringer, Daichi, Lilly, medac, Merck, MSD, Pierre Fabre, Roche, Saladax, Sanofi, and Servier; and consulting fees from Amgen, Astra Zeneca, Bayer, BMS, Boehringer, Daichi, Lilly, medac, Merck, MSD, Pierre Fabre, Roche, Saladax, Sanofi, and Servier. AV reports serving as an advisor with Roche, Bayer, Bristol Myers Squibb, Lilly, Eisai, AstraZeneca, IPSEN, MSD, Sirtex, BTG, Servier, Terumo, and Imaging Equipment; and consulting fees and honoraria for lectures from Roche, Bayer, Bristol Myers Squibb, Lilly, Eisai, Astra Zeneca, IPSEN, MSD, Sirtex, BTG, Servier, Terumo, and Imaging Equipment. RJ reports receiving consulting fees from Roche and Bayer; payments for lectures and presentations from Dr Falk Pharma and Bristol Myers Squibb; for writing of manuscripts from Boston Scientific and Springer Nature; serving as an advisor with Heidelberg University Hospital; and leading the Endoscopy section of the German Society of Gastroenterology. PTP reports receiving consulting fees from Bristol Myers Squibb, AstraZeneca, and MSD. TGa reports receiving honoraria from Bristol Myers Squibb, MSD, and Roche for presentations and advisory functions. JNK reports receiving consulting fees from Owkin and Panakeia as well as honoraria for lectures from MSD and Eisai. MM reports employment with AIO Studien, who was the regulatory sponsor of the trial. NH reports serving as an advisor with Bristol Myers Squibb. All other authors declare no competing interests.